HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDAer Resigns Over Plan B; Senators Seek Results Of GAO Investigation

This article was originally published in The Tan Sheet

Executive Summary

FDA Office of Women's Health Director Susan Wood is resigning over the agency's handling of Barr Labs' application to switch its Plan B emergency contraceptive over-the-counter

You may also be interested in...



Like Plan B, Approval For OTC Daily Oral Contraceptives In US Could Be An 'Adventure’

It was only after prolonged litigation led a federal judge in 2013 to order FDA not to allow political interference with its science-based decisions that Plan B and generic equivalents became available OTC without age restrictions. “Hopefully, all I can say, it won't happen again,” says reproductive rights advocate Kirsten Moore.

Plan B Lightning May Strike Again: Complying Will Not End Political Storm

Perpetual political lightning rod - and emergency contraceptive - Plan B has another chance to draw strikes to FDA as the agency has chosen to comply with a court ruling ordering it to reconsider whether the drug should be available in a truly over-the counter setting

Plan B Ruling: Little Commercial Impact, Big Policy Implications

The court ruling overturning FDA's restricted distribution of the emergency contraceptive Plan B could have a number of implications for the biopharma industry - ranging from a near-term impact on confirmation of Obama administration nominees to a longer-term curbing of creative product risk management activities

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS126608

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel